Nothing Special   »   [go: up one dir, main page]

GB2276624B - Inactivation of cytotoxic drugs in the vascular compartment of a host - Google Patents

Inactivation of cytotoxic drugs in the vascular compartment of a host

Info

Publication number
GB2276624B
GB2276624B GB9410237A GB9410237A GB2276624B GB 2276624 B GB2276624 B GB 2276624B GB 9410237 A GB9410237 A GB 9410237A GB 9410237 A GB9410237 A GB 9410237A GB 2276624 B GB2276624 B GB 2276624B
Authority
GB
United Kingdom
Prior art keywords
inactivation
host
cytotoxic drugs
vascular compartment
vascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB9410237A
Other versions
GB2276624A (en
GB9410237D0 (en
Inventor
Kenneth Dawson Bagshawe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB9410237A priority Critical patent/GB2276624B/en
Publication of GB9410237D0 publication Critical patent/GB9410237D0/en
Publication of GB2276624A publication Critical patent/GB2276624A/en
Application granted granted Critical
Publication of GB2276624B publication Critical patent/GB2276624B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GB9410237A 1992-01-09 1993-01-11 Inactivation of cytotoxic drugs in the vascular compartment of a host Expired - Fee Related GB2276624B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB9410237A GB2276624B (en) 1992-01-09 1993-01-11 Inactivation of cytotoxic drugs in the vascular compartment of a host

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929200415A GB9200415D0 (en) 1992-01-09 1992-01-09 Inactivation of cytotoxic drugs
GB929204104A GB9204104D0 (en) 1992-01-09 1992-02-26 Inactivation of cytotoxic drugs
GB9410237A GB2276624B (en) 1992-01-09 1993-01-11 Inactivation of cytotoxic drugs in the vascular compartment of a host
PCT/GB1993/000040 WO1993013806A1 (en) 1992-01-09 1993-01-11 Inactivation of cytotoxic drugs

Publications (3)

Publication Number Publication Date
GB9410237D0 GB9410237D0 (en) 1994-07-27
GB2276624A GB2276624A (en) 1994-10-05
GB2276624B true GB2276624B (en) 1995-10-25

Family

ID=26300132

Family Applications (3)

Application Number Title Priority Date Filing Date
GB929200415A Pending GB9200415D0 (en) 1992-01-09 1992-01-09 Inactivation of cytotoxic drugs
GB929204104A Pending GB9204104D0 (en) 1992-01-09 1992-02-26 Inactivation of cytotoxic drugs
GB9410237A Expired - Fee Related GB2276624B (en) 1992-01-09 1993-01-11 Inactivation of cytotoxic drugs in the vascular compartment of a host

Family Applications Before (2)

Application Number Title Priority Date Filing Date
GB929200415A Pending GB9200415D0 (en) 1992-01-09 1992-01-09 Inactivation of cytotoxic drugs
GB929204104A Pending GB9204104D0 (en) 1992-01-09 1992-02-26 Inactivation of cytotoxic drugs

Country Status (5)

Country Link
EP (1) EP0620742A1 (en)
JP (1) JPH07506339A (en)
CA (1) CA2124217A1 (en)
GB (3) GB9200415D0 (en)
WO (1) WO1993013806A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264220A (en) * 1991-11-12 1993-11-23 Long David M Jr Method of extending the vascular dwell-time of particulate therapeutic and particulate diagnostic agents
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
GB9624993D0 (en) * 1996-11-30 1997-01-15 Aepact Ltd Tumour therapy
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
ATE346036T1 (en) * 1998-05-22 2006-12-15 Abbott Lab ANTIANGIOGENIC SUBSTANCE FOR THE TREATMENT OF CANCER, ARTHRITIS AND RETINAL DISEASES
CO5170498A1 (en) * 1999-05-28 2002-06-27 Abbott Lab BIARIL SULFONAMIDS ARE USEFUL AS CELL PROLIFERATION INHIBITORS
FR2883873B1 (en) * 2005-03-31 2009-07-10 Pharmamens Sarl AGE INHIBITORS
US7732309B2 (en) * 2006-12-08 2010-06-08 Applied Materials, Inc. Plasma immersed ion implantation process
AU2011288464B2 (en) * 2010-08-10 2015-10-29 Glycotope Gmbh Fab-glycosylated antibodies
EP4257611A3 (en) 2018-05-18 2024-03-06 Glycotope GmbH Anti-muc1 antibody

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007378A1 (en) * 1987-03-09 1988-10-06 Cancer Research Campaign Technology Ltd. Improvements relating to drug delivery systems
EP0308208A1 (en) * 1987-09-14 1989-03-22 Center For Molecular Medicine And Immunology Modified antibody conjugates with enhanced clearance
WO1989010140A1 (en) * 1988-04-22 1989-11-02 Cancer Research Campaign Technology Limited Further improvements relating to drug delivery systems
WO1990009134A1 (en) * 1989-02-13 1990-08-23 Cosgrove James H Device for releasably supporting a plurality of objects
WO1990010460A1 (en) * 1989-03-13 1990-09-20 Kenneth Naoyuki Matsumura Method for reducing side effects of a drug
EP0506124A1 (en) * 1991-03-27 1992-09-30 Tanox Biosystems, Inc. Methods and substances for recruiting therapeutic agents to solid issues comprising two single chain VH-VL bifunctional binding molecules

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009134A1 (en) * 1989-12-15 1991-06-27 Takeda Chemical Industries, Ltd. Biospecific antibody to cancer cell and enzyme with prodrug-activating characteristics

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007378A1 (en) * 1987-03-09 1988-10-06 Cancer Research Campaign Technology Ltd. Improvements relating to drug delivery systems
EP0308208A1 (en) * 1987-09-14 1989-03-22 Center For Molecular Medicine And Immunology Modified antibody conjugates with enhanced clearance
WO1989010140A1 (en) * 1988-04-22 1989-11-02 Cancer Research Campaign Technology Limited Further improvements relating to drug delivery systems
WO1990009134A1 (en) * 1989-02-13 1990-08-23 Cosgrove James H Device for releasably supporting a plurality of objects
WO1990010460A1 (en) * 1989-03-13 1990-09-20 Kenneth Naoyuki Matsumura Method for reducing side effects of a drug
EP0506124A1 (en) * 1991-03-27 1992-09-30 Tanox Biosystems, Inc. Methods and substances for recruiting therapeutic agents to solid issues comprising two single chain VH-VL bifunctional binding molecules

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Antibody,Immunoconjugates,Radiopharm. 1988,1(2),169-180 *
Proc.Natl.Acad.Sci.USA 1983,80,3078-3080 *

Also Published As

Publication number Publication date
JPH07506339A (en) 1995-07-13
GB2276624A (en) 1994-10-05
GB9200415D0 (en) 1992-02-26
GB9204104D0 (en) 1992-04-08
WO1993013806A1 (en) 1993-07-22
GB9410237D0 (en) 1994-07-27
CA2124217A1 (en) 1993-07-22
EP0620742A1 (en) 1994-10-26

Similar Documents

Publication Publication Date Title
GB9200417D0 (en) Cytotoxic drug therapy
GB8820945D0 (en) Medical articles
IL107411A0 (en) Infusion administering catheter holder
EP0351687A3 (en) Vascular catheter
AU4854393A (en) Self-introducing infusion catheter
AU4227793A (en) Drug infuser
HK1000279A1 (en) Medical bag
AU7673694A (en) Simultaneous angioplasty and drug delivery
ZA895909B (en) Cytotoxic drug conjugates
AU8253791A (en) Delivery catheter
ZA895908B (en) Cytotoxic drug conjugates
GB2276624B (en) Inactivation of cytotoxic drugs in the vascular compartment of a host
NZ257470A (en) 5-hydrazino-quinolone derivatives and antimicrobial medicaments
HU00207A9 (en) Sulfonanilide derivatives and medicine
AU7472994A (en) Polyesters for use in blood partitioning
HUT57669A (en) Auotmatic shelf container
GB9119793D0 (en) Medicine containers
NZ248041A (en) Aminoalkyl- tetrahydrofuran derivatives and medicaments
AU667546C (en) Medicine container
GB9213627D0 (en) Cholangiography catheter
GB9314472D0 (en) Pharmaceutical container
GB9013977D0 (en) Medicament container
GB9000627D0 (en) Medicament container
IE883708L (en) Medicament container
GB8821698D0 (en) Medicament container

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20010111